EGFR-directed radioimmunotherapy combined with chemotherapy and DNA repair inhibition: development towards clinical application for aggressive cancers

EGFR靶向放射免疫疗法联合化疗和DNA修复抑制：侵袭性癌症的临床应用发展

• 批准号: FT130101417
• 负责人: Dr Fares Al-Ejeh
• 金额: $ 52.49万
• 依托单位: Queensland Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: ARC Future Fellowships
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/FT130101417
• 关键词: EGFR; directed; radioimmunotherapy; combined; chemotherapy

Pancreatic ductal adenocarcinoma (PDAC) and triple negative breast cancer (TNBC) are aggressive diseases which lack effective therapies in clinical use. A novel and curative therapy was developed against PDAC and TNBC which involves targeted radiotherapy combined with chemotherapy and DNA damage response inhibition. This project will develop a “preclinical data package” comprising a biological rationale and preclinical evidence of safety and efficacy that together would justify an early phase clinical trial. This package includes the choice of formulations, mechanism of action and safety studies. This development will have an immediate impact for PDAC and TNBC patients and a future impact on other EGFR-positive cancers.

胰腺导管腺癌（PDAC）和三阴性乳腺癌（TNBC）是临床上缺乏有效治疗的侵袭性疾病。针对PDAC和TNBC开发了一种新的治愈性疗法，其涉及靶向放疗与化疗和DNA损伤反应抑制的组合。该项目将开发一个“临床前数据包”，包括生物学原理和临床前安全性和有效性证据，这些证据将共同证明早期临床试验的合理性。这套方案包括配方的选择、作用机制和安全性研究。这一发展将对PDAC和TNBC患者产生直接影响，并对其他EGFR阳性癌症产生未来影响。